JP2006511552A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2006511552A5 JP2006511552A5 JP2004560830A JP2004560830A JP2006511552A5 JP 2006511552 A5 JP2006511552 A5 JP 2006511552A5 JP 2004560830 A JP2004560830 A JP 2004560830A JP 2004560830 A JP2004560830 A JP 2004560830A JP 2006511552 A5 JP2006511552 A5 JP 2006511552A5
- Authority
- JP
- Japan
- Prior art keywords
- triazaspiro
- dichlorophenyl
- pyrrolidin
- decan
- optionally substituted
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- SFVBFGGJQKQUNE-UHFFFAOYSA-N 8-[3-[1-(cyclobutanecarbonyl)-3-(3,4-dichlorophenyl)pyrrolidin-3-yl]propyl]-1-[3-(trifluoromethyl)phenyl]-1,3,8-triazaspiro[4.5]decan-4-one Chemical compound FC(F)(F)C1=CC=CC(N2C3(CCN(CCCC4(CN(CC4)C(=O)C4CCC4)C=4C=C(Cl)C(Cl)=CC=4)CC3)C(=O)NC2)=C1 SFVBFGGJQKQUNE-UHFFFAOYSA-N 0.000 claims description 2
- AEPIMLRQXURBLH-UHFFFAOYSA-N 8-[3-[3-(3,4-dichlorophenyl)-1-(furan-2-carbonyl)pyrrolidin-3-yl]propyl]-1-[3-(trifluoromethyl)phenyl]-1,3,8-triazaspiro[4.5]decan-4-one Chemical compound FC(F)(F)C1=CC=CC(N2C3(CCN(CCCC4(CN(CC4)C(=O)C=4OC=CC=4)C=4C=C(Cl)C(Cl)=CC=4)CC3)C(=O)NC2)=C1 AEPIMLRQXURBLH-UHFFFAOYSA-N 0.000 claims description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical group N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 24
- 229920006395 saturated elastomer Polymers 0.000 claims 15
- 125000003118 aryl group Chemical group 0.000 claims 13
- 229910052757 nitrogen Chemical group 0.000 claims 13
- 125000000217 alkyl group Chemical group 0.000 claims 9
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical group [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 claims 8
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims 8
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 8
- 125000005842 heteroatom Chemical group 0.000 claims 8
- 229910052760 oxygen Inorganic materials 0.000 claims 8
- 239000001301 oxygen Substances 0.000 claims 8
- 229910052698 phosphorus Inorganic materials 0.000 claims 8
- 239000011574 phosphorus Chemical group 0.000 claims 8
- 239000011593 sulfur Chemical group 0.000 claims 8
- 229910052717 sulfur Inorganic materials 0.000 claims 8
- 125000001072 heteroaryl group Chemical group 0.000 claims 7
- 125000003342 alkenyl group Chemical group 0.000 claims 6
- 125000000304 alkynyl group Chemical group 0.000 claims 6
- 125000000753 cycloalkyl group Chemical group 0.000 claims 6
- 150000001875 compounds Chemical class 0.000 claims 5
- 229910052736 halogen Inorganic materials 0.000 claims 5
- 150000002367 halogens Chemical class 0.000 claims 5
- 125000000623 heterocyclic group Chemical group 0.000 claims 5
- 239000003814 drug Substances 0.000 claims 3
- 238000004519 manufacturing process Methods 0.000 claims 3
- -1 methylenedioxy, ethylenedioxy Chemical group 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 206010052779 Transplant rejections Diseases 0.000 claims 2
- 241000607479 Yersinia pestis Species 0.000 claims 2
- 125000002947 alkylene group Chemical group 0.000 claims 2
- 125000003710 aryl alkyl group Chemical group 0.000 claims 2
- 125000004475 heteroaralkyl group Chemical group 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 2
- 125000003003 spiro group Chemical group 0.000 claims 2
- 230000009385 viral infection Effects 0.000 claims 2
- RBWQFZGAMMYYBQ-UHFFFAOYSA-N 3-acetyl-8-[3-[1-acetyl-3-(3,4-dichlorophenyl)pyrrolidin-3-yl]propyl]-1-(3-methylphenyl)-1,3,8-triazaspiro[4.5]decan-4-one Chemical compound C1N(C(=O)C)CCC1(C=1C=C(Cl)C(Cl)=CC=1)CCCN1CCC2(C(N(C(C)=O)CN2C=2C=C(C)C=CC=2)=O)CC1 RBWQFZGAMMYYBQ-UHFFFAOYSA-N 0.000 claims 1
- 125000004207 3-methoxyphenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(OC([H])([H])[H])=C1[H] 0.000 claims 1
- RXBIVTVHJAPOFO-UHFFFAOYSA-N 8-[2-[1-(benzenesulfonyl)-3-(3,4-dichlorophenyl)pyrrolidin-3-yl]oxyethyl]-1-phenyl-1,3,8-triazaspiro[4.5]decan-4-one Chemical compound C1=C(Cl)C(Cl)=CC=C1C1(OCCN2CCC3(CC2)C(NCN3C=2C=CC=CC=2)=O)CN(S(=O)(=O)C=2C=CC=CC=2)CC1 RXBIVTVHJAPOFO-UHFFFAOYSA-N 0.000 claims 1
- UBECTFKELCFEJP-UHFFFAOYSA-N 8-[2-[1-(cyclopentanecarbonyl)-3-(3,4-dichlorophenyl)pyrrolidin-3-yl]oxyethyl]-1-(3-methoxyphenyl)-1,3,8-triazaspiro[4.5]decan-4-one Chemical compound COC1=CC=CC(N2C3(CCN(CCOC4(CN(CC4)C(=O)C4CCCC4)C=4C=C(Cl)C(Cl)=CC=4)CC3)C(=O)NC2)=C1 UBECTFKELCFEJP-UHFFFAOYSA-N 0.000 claims 1
- BDGIQNNCLSFLPH-UHFFFAOYSA-N 8-[2-[1-(cyclopentanecarbonyl)-3-(3,4-dichlorophenyl)pyrrolidin-3-yl]oxyethyl]-1-phenyl-1,3,8-triazaspiro[4.5]decan-4-one Chemical compound C1=C(Cl)C(Cl)=CC=C1C1(OCCN2CCC3(CC2)C(NCN3C=2C=CC=CC=2)=O)CN(C(=O)C2CCCC2)CC1 BDGIQNNCLSFLPH-UHFFFAOYSA-N 0.000 claims 1
- SBUICUBXZZDNFD-UHFFFAOYSA-N 8-[2-[1-acetyl-3-(3,4-dichlorophenyl)pyrrolidin-3-yl]oxyethyl]-1-(3-methoxyphenyl)-1,3,8-triazaspiro[4.5]decan-4-one Chemical compound COC1=CC=CC(N2C3(CCN(CCOC4(CN(CC4)C(C)=O)C=4C=C(Cl)C(Cl)=CC=4)CC3)C(=O)NC2)=C1 SBUICUBXZZDNFD-UHFFFAOYSA-N 0.000 claims 1
- DVTGJLGNKBFZNW-UHFFFAOYSA-N 8-[2-[1-acetyl-3-(3,4-dichlorophenyl)pyrrolidin-3-yl]oxyethyl]-1-phenyl-1,3,8-triazaspiro[4.5]decan-4-one Chemical compound C1N(C(=O)C)CCC1(C=1C=C(Cl)C(Cl)=CC=1)OCCN1CCC2(C(NCN2C=2C=CC=CC=2)=O)CC1 DVTGJLGNKBFZNW-UHFFFAOYSA-N 0.000 claims 1
- GHEGZKINMNYSGV-UHFFFAOYSA-N 8-[2-[3-(3,4-dichlorophenyl)-1-(furan-2-carbonyl)pyrrolidin-3-yl]oxyethyl]-1-(3-methoxyphenyl)-1,3,8-triazaspiro[4.5]decan-4-one Chemical compound COC1=CC=CC(N2C3(CCN(CCOC4(CN(CC4)C(=O)C=4OC=CC=4)C=4C=C(Cl)C(Cl)=CC=4)CC3)C(=O)NC2)=C1 GHEGZKINMNYSGV-UHFFFAOYSA-N 0.000 claims 1
- AAFIDRUCDKVRAX-UHFFFAOYSA-N 8-[2-[3-(3,4-dichlorophenyl)-1-(furan-2-carbonyl)pyrrolidin-3-yl]oxyethyl]-1-phenyl-1,3,8-triazaspiro[4.5]decan-4-one Chemical compound C1=C(Cl)C(Cl)=CC=C1C1(OCCN2CCC3(CC2)C(NCN3C=2C=CC=CC=2)=O)CN(C(=O)C=2OC=CC=2)CC1 AAFIDRUCDKVRAX-UHFFFAOYSA-N 0.000 claims 1
- WVQYDTHXIAJNCX-UHFFFAOYSA-N 8-[3-[1-(1,3-benzoxazol-2-yl)-3-(3,4-dichlorophenyl)pyrrolidin-3-yl]propyl]-1-phenyl-1,3,8-triazaspiro[4.5]decan-4-one Chemical compound C1=C(Cl)C(Cl)=CC=C1C1(CCCN2CCC3(CC2)C(NCN3C=2C=CC=CC=2)=O)CN(C=2OC3=CC=CC=C3N=2)CC1 WVQYDTHXIAJNCX-UHFFFAOYSA-N 0.000 claims 1
- VOYBLFGYVCDFDQ-UHFFFAOYSA-N 8-[3-[1-(cyclobutanecarbonyl)-3-(3,4-dichlorophenyl)pyrrolidin-3-yl]propyl]-1-(3-methylphenyl)-1,3,8-triazaspiro[4.5]decan-4-one Chemical compound CC1=CC=CC(N2C3(CCN(CCCC4(CN(CC4)C(=O)C4CCC4)C=4C=C(Cl)C(Cl)=CC=4)CC3)C(=O)NC2)=C1 VOYBLFGYVCDFDQ-UHFFFAOYSA-N 0.000 claims 1
- XIGGEHYEYAGKDW-UHFFFAOYSA-N 8-[3-[1-(cyclobutanecarbonyl)-3-(3,4-dichlorophenyl)pyrrolidin-3-yl]propyl]-1-phenyl-1,3,8-triazaspiro[4.5]decan-4-one Chemical compound C1=C(Cl)C(Cl)=CC=C1C1(CCCN2CCC3(CC2)C(NCN3C=2C=CC=CC=2)=O)CN(C(=O)C2CCC2)CC1 XIGGEHYEYAGKDW-UHFFFAOYSA-N 0.000 claims 1
- WNPXNEPKVBXIMB-UHFFFAOYSA-N 8-[3-[1-(cyclopentanecarbonyl)-3-(3,4-dichlorophenyl)pyrrolidin-3-yl]propyl]-1-phenyl-1,3,8-triazaspiro[4.5]decan-4-one Chemical compound C1=C(Cl)C(Cl)=CC=C1C1(CCCN2CCC3(CC2)C(NCN3C=2C=CC=CC=2)=O)CN(C(=O)C2CCCC2)CC1 WNPXNEPKVBXIMB-UHFFFAOYSA-N 0.000 claims 1
- XHDQHNDEKMSTLH-UHFFFAOYSA-N 8-[3-[3-(3,4-dichlorophenyl)-1-(1,2-oxazole-5-carbonyl)pyrrolidin-3-yl]propyl]-1-phenyl-1,3,8-triazaspiro[4.5]decan-4-one Chemical compound C1=C(Cl)C(Cl)=CC=C1C1(CCCN2CCC3(CC2)C(NCN3C=2C=CC=CC=2)=O)CN(C(=O)C=2ON=CC=2)CC1 XHDQHNDEKMSTLH-UHFFFAOYSA-N 0.000 claims 1
- JUNHJHFCWPRNMB-UHFFFAOYSA-N 8-[3-[3-(3,4-dichlorophenyl)-1-(1h-pyrrole-2-carbonyl)pyrrolidin-3-yl]propyl]-1-phenyl-1,3,8-triazaspiro[4.5]decan-4-one Chemical compound C1=C(Cl)C(Cl)=CC=C1C1(CCCN2CCC3(CC2)C(NCN3C=2C=CC=CC=2)=O)CN(C(=O)C=2NC=CC=2)CC1 JUNHJHFCWPRNMB-UHFFFAOYSA-N 0.000 claims 1
- XNEIHDJRJHCBGO-UHFFFAOYSA-N 8-[3-[3-(3,4-dichlorophenyl)-1-(furan-2-carbonyl)pyrrolidin-3-yl]propyl]-1-phenyl-1,3,8-triazaspiro[4.5]decan-4-one Chemical compound C1=C(Cl)C(Cl)=CC=C1C1(CCCN2CCC3(CC2)C(NCN3C=2C=CC=CC=2)=O)CN(C(=O)C=2OC=CC=2)CC1 XNEIHDJRJHCBGO-UHFFFAOYSA-N 0.000 claims 1
- HNDXHGWVNQBTNH-UHFFFAOYSA-N 8-[3-[3-(3,4-dichlorophenyl)-1-pentanoylpyrrolidin-3-yl]propyl]-1-[3-(trifluoromethyl)phenyl]-1,3,8-triazaspiro[4.5]decan-4-one Chemical compound C1N(C(=O)CCCC)CCC1(C=1C=C(Cl)C(Cl)=CC=1)CCCN1CCC2(C(NCN2C=2C=C(C=CC=2)C(F)(F)F)=O)CC1 HNDXHGWVNQBTNH-UHFFFAOYSA-N 0.000 claims 1
- DLJZDHUTSDLZRK-UHFFFAOYSA-N 8-[3-[3-(3,4-dichlorophenyl)-1-pentanoylpyrrolidin-3-yl]propyl]-1-phenyl-1,3,8-triazaspiro[4.5]decan-4-one Chemical compound C1N(C(=O)CCCC)CCC1(C=1C=C(Cl)C(Cl)=CC=1)CCCN1CCC2(C(NCN2C=2C=CC=CC=2)=O)CC1 DLJZDHUTSDLZRK-UHFFFAOYSA-N 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 206010003178 Arterial thrombosis Diseases 0.000 claims 1
- 206010003210 Arteriosclerosis Diseases 0.000 claims 1
- 241000894006 Bacteria Species 0.000 claims 1
- 208000035143 Bacterial infection Diseases 0.000 claims 1
- 208000035473 Communicable disease Diseases 0.000 claims 1
- 208000011231 Crohn disease Diseases 0.000 claims 1
- 208000022461 Glomerular disease Diseases 0.000 claims 1
- 208000031886 HIV Infections Diseases 0.000 claims 1
- 208000037357 HIV infectious disease Diseases 0.000 claims 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 208000009608 Papillomavirus Infections Diseases 0.000 claims 1
- 206010035148 Plague Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 206010039085 Rhinitis allergic Diseases 0.000 claims 1
- 208000021386 Sjogren Syndrome Diseases 0.000 claims 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 1
- 208000036142 Viral infection Diseases 0.000 claims 1
- 201000010105 allergic rhinitis Diseases 0.000 claims 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims 1
- 208000011775 arteriosclerosis disease Diseases 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 230000001363 autoimmune Effects 0.000 claims 1
- 208000022362 bacterial infectious disease Diseases 0.000 claims 1
- 201000006824 bubonic plague Diseases 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 239000002775 capsule Substances 0.000 claims 1
- 125000002837 carbocyclic group Chemical group 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- 208000037976 chronic inflammation Diseases 0.000 claims 1
- 208000037893 chronic inflammatory disorder Diseases 0.000 claims 1
- MKJDUHZPLQYUCB-UHFFFAOYSA-N decan-4-one Chemical compound CCCCCCC(=O)CCC MKJDUHZPLQYUCB-UHFFFAOYSA-N 0.000 claims 1
- 201000001981 dermatomyositis Diseases 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 201000002491 encephalomyelitis Diseases 0.000 claims 1
- 231100000852 glomerular disease Toxicity 0.000 claims 1
- 125000005843 halogen group Chemical group 0.000 claims 1
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 1
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 claims 1
- 208000021145 human papilloma virus infection Diseases 0.000 claims 1
- 229910052739 hydrogen Inorganic materials 0.000 claims 1
- 239000001257 hydrogen Substances 0.000 claims 1
- 150000002431 hydrogen Chemical class 0.000 claims 1
- 230000008595 infiltration Effects 0.000 claims 1
- 238000001764 infiltration Methods 0.000 claims 1
- 208000017169 kidney disease Diseases 0.000 claims 1
- 210000000265 leukocyte Anatomy 0.000 claims 1
- 239000007788 liquid Substances 0.000 claims 1
- 210000004072 lung Anatomy 0.000 claims 1
- 230000001404 mediated effect Effects 0.000 claims 1
- 238000013160 medical therapy Methods 0.000 claims 1
- 125000002950 monocyclic group Chemical group 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 230000003589 nefrotoxic effect Effects 0.000 claims 1
- 201000008383 nephritis Diseases 0.000 claims 1
- 231100000381 nephrotoxic Toxicity 0.000 claims 1
- 210000000056 organ Anatomy 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 210000002966 serum Anatomy 0.000 claims 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 1
- 230000029663 wound healing Effects 0.000 claims 1
- 0 CC*(*)CCC(*)(CNC(*)*(C)*)*C1CCCC(*)(*)CCCC1 Chemical compound CC*(*)CCC(*)(CNC(*)*(C)*)*C1CCCC(*)(*)CCCC1 0.000 description 32
- TVSZCWAGXHBDIO-UHFFFAOYSA-N O=C(C12CCN(CCCC(C3)(CN3S(c3ccccc3)(=O)=O)c(cc3Cl)ccc3Cl)CC1)NCN2c1ccccc1 Chemical compound O=C(C12CCN(CCCC(C3)(CN3S(c3ccccc3)(=O)=O)c(cc3Cl)ccc3Cl)CC1)NCN2c1ccccc1 TVSZCWAGXHBDIO-UHFFFAOYSA-N 0.000 description 2
- XAXLZYHPFKZUBP-UHFFFAOYSA-N COc1cccc(N(CC2C3CC2)C2(CCN(CCCC(CC4)(CN4C(C4CCC4)=O)c(cc4Cl)ccc4Cl)CC2)C3=O)c1 Chemical compound COc1cccc(N(CC2C3CC2)C2(CCN(CCCC(CC4)(CN4C(C4CCC4)=O)c(cc4Cl)ccc4Cl)CC2)C3=O)c1 XAXLZYHPFKZUBP-UHFFFAOYSA-N 0.000 description 1
- RSOOJZKCQVHGKS-UHFFFAOYSA-N COc1cccc(N(CN2)C3(CCN(CCCC(CC4)(CN4C(c4ccn[o]4)=O)c(cc4Cl)ccc4Cl)CC3)C2O)c1 Chemical compound COc1cccc(N(CN2)C3(CCN(CCCC(CC4)(CN4C(c4ccn[o]4)=O)c(cc4Cl)ccc4Cl)CC3)C2O)c1 RSOOJZKCQVHGKS-UHFFFAOYSA-N 0.000 description 1
- OLLHSHDISWQNLT-UHFFFAOYSA-N Cc1cccc(N(CCCC2C(C3CCCC3)=O)CCN(CCCC(CC3)(CN3C(C3CCCC3)=O)c(cc3Cl)ccc3Cl)CCC2=O)c1 Chemical compound Cc1cccc(N(CCCC2C(C3CCCC3)=O)CCN(CCCC(CC3)(CN3C(C3CCCC3)=O)c(cc3Cl)ccc3Cl)CCC2=O)c1 OLLHSHDISWQNLT-UHFFFAOYSA-N 0.000 description 1
- RTHSFGQQEWYIID-UHFFFAOYSA-N Cc1cccc(N(CN2)C3(CCN(CCCC(CC4)(CN4C(C4CCCC4)=O)c(cc4)cc(Cl)c4Cl)CC3)C2=O)c1 Chemical compound Cc1cccc(N(CN2)C3(CCN(CCCC(CC4)(CN4C(C4CCCC4)=O)c(cc4)cc(Cl)c4Cl)CC3)C2=O)c1 RTHSFGQQEWYIID-UHFFFAOYSA-N 0.000 description 1
- IYJURJAJTWYHBZ-UHFFFAOYSA-N O=C(C12CCN(CCCC(CC3)(CN3c3nc4ccccc4[s]3)c(cc3)cc(Cl)c3Cl)CC1)NCN2c1ccccc1 Chemical compound O=C(C12CCN(CCCC(CC3)(CN3c3nc4ccccc4[s]3)c(cc3)cc(Cl)c3Cl)CC1)NCN2c1ccccc1 IYJURJAJTWYHBZ-UHFFFAOYSA-N 0.000 description 1
- OBAOZNSPCAVIIT-UHFFFAOYSA-N O=C(C1CCC1)N(CC1)CC1(CCCN(CC1)CCC1(C(NC1)=O)N1c1cc(C(F)(F)F)ccc1)c(cc1)ccc1Cl Chemical compound O=C(C1CCC1)N(CC1)CC1(CCCN(CC1)CCC1(C(NC1)=O)N1c1cc(C(F)(F)F)ccc1)c(cc1)ccc1Cl OBAOZNSPCAVIIT-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US43337202P | 2002-12-13 | 2002-12-13 | |
| PCT/US2003/039618 WO2004055016A1 (en) | 2002-12-13 | 2003-12-12 | Pyrrolidine and azetidine compounds as ccr5 antagonists |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2006511552A JP2006511552A (ja) | 2006-04-06 |
| JP2006511552A5 true JP2006511552A5 (https=) | 2007-01-11 |
Family
ID=32595168
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2004560830A Pending JP2006511552A (ja) | 2002-12-13 | 2003-12-12 | Ｃｃｒ５拮抗薬としてのピロリジンおよびアゼチジン化合物 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US7271172B2 (https=) |
| EP (1) | EP1569933B1 (https=) |
| JP (1) | JP2006511552A (https=) |
| AT (1) | ATE402176T1 (https=) |
| AU (1) | AU2003296992A1 (https=) |
| DE (1) | DE60322423D1 (https=) |
| ES (1) | ES2309400T3 (https=) |
| WO (1) | WO2004055016A1 (https=) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2003297048A1 (en) * | 2002-12-13 | 2004-07-09 | Smithkline Beecham Corporation | Cyclohexyl compounds as ccr5 antagonists |
| GB0417801D0 (en) * | 2004-08-10 | 2004-09-15 | Novartis Ag | Organic compounds |
| AU2005299852B2 (en) * | 2004-10-22 | 2011-08-04 | Merck Sharp & Dohme Corp. | CGRP receptor antagonists |
| US8211904B2 (en) * | 2005-07-18 | 2012-07-03 | Merck, Sharp & Dohme Corp. | Spiropiperidine beta-secretase inhibitors for the treatment of alzheimer's disease |
| US20080108586A1 (en) * | 2006-09-06 | 2008-05-08 | Incyte Corporation | Combination therapy for human immunodeficiency virus infection |
| CA2662835A1 (en) * | 2006-09-18 | 2008-03-27 | Remy Lemoine | Octahydropyrrolo [3, 4-c] pyrrole derivatives and their use as antiviral agents |
| EP2114925B8 (en) * | 2006-12-22 | 2013-04-10 | Industrial Research Limited | Azetidine analogues of nucleosidase and phosphorylase inhibitors |
| KR20110022620A (ko) | 2008-05-30 | 2011-03-07 | 다케다 야쿠힌 고교 가부시키가이샤 | 복소환 화합물 |
| UA103195C2 (uk) | 2008-08-11 | 2013-09-25 | Глаксосмитклайн Ллк | Похідні пурину для застосування у лікуванні алергій, запальних та інфекційних захворювань |
| JP2011530562A (ja) | 2008-08-11 | 2011-12-22 | グラクソスミスクライン エルエルシー | アレルギー性、炎症性及び感染性疾患治療用のプリン誘導体 |
| SI2320905T1 (sl) | 2008-08-11 | 2017-10-30 | Glaxosmithkline Llc Corporation Service Company | Novi adeninski derivati |
| US8575340B2 (en) | 2010-02-10 | 2013-11-05 | Glaxosmithkline Llc | Purine derivatives and their pharmaceutical uses |
| EP2534149B1 (en) | 2010-02-10 | 2014-10-15 | GlaxoSmithKline LLC | 6-amino-2-{[(1s)-1-methylbutyl]oxy}-9-[5-(1-piperidinyl)pentyl]-7,9-dihydro-8h-purin-8-one maleate |
| JO3387B1 (ar) | 2011-12-16 | 2019-03-13 | Glaxosmithkline Llc | مشتقات بيتولين |
| KR20160124157A (ko) | 2014-02-20 | 2016-10-26 | 글락소스미스클라인 인털렉츄얼 프로퍼티 (넘버 2) 리미티드 | 인간 인터페론의 유도인자로서의 피롤로[3,2]피리미딘 유도체 |
| MX2017006302A (es) | 2014-11-13 | 2018-02-16 | Glaxosmithkline Biologicals Sa | Derivados de adenina que son utiles en el tratamiento de enfermedades alergicas u otras afecciones inflamatorias. |
| TW201712012A (zh) * | 2015-06-16 | 2017-04-01 | 美國禮來大藥廠 | ２－側氧基－１，３，８－三氮雜螺［４．５］癸－３－基羧酸衍生物 |
| TWI704154B (zh) | 2015-12-03 | 2020-09-11 | 英商葛蘭素史克智慧財產發展有限公司 | 新穎化合物 |
| HRP20220936T1 (hr) | 2016-04-07 | 2022-10-28 | Glaxosmithkline Intellectual Property Development Limited | Heterociklički amidi korisni kao modulatori proteina |
| JP2019510802A (ja) | 2016-04-07 | 2019-04-18 | グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ | タンパク質調節物質として有用な複素環アミド |
| US20210238172A1 (en) | 2017-10-05 | 2021-08-05 | Glaxosmithkline Intellectual Property Development Limited | Heterocyclic amides useful as protein modulators and methods of using the same |
| CA3077337A1 (en) | 2017-10-05 | 2019-04-11 | Glaxosmithkline Intellectual Property Development Limited | Modulators of stimulator of interferon genes (sting) |
| GB201807924D0 (en) | 2018-05-16 | 2018-06-27 | Ctxt Pty Ltd | Compounds |
| WO2020113094A1 (en) | 2018-11-30 | 2020-06-04 | Nuvation Bio Inc. | Pyrrole and pyrazole compounds and methods of use thereof |
| US20220227761A1 (en) | 2019-05-16 | 2022-07-21 | Stingthera, Inc. | Oxoacridinyl acetic acid derivatives and methods of use |
| JP2022533194A (ja) | 2019-05-16 | 2022-07-21 | スティングセラ インコーポレイテッド | ベンゾ［ｂ］［１，８］ナフチリジン酢酸誘導体および使用方法 |
| GB201910304D0 (en) | 2019-07-18 | 2019-09-04 | Ctxt Pty Ltd | Compounds |
| GB201910305D0 (en) | 2019-07-18 | 2019-09-04 | Ctxt Pty Ltd | Compounds |
| CN114981265B (zh) | 2019-12-18 | 2025-01-03 | Ctxt私人有限公司 | 化合物 |
| US11116737B1 (en) | 2020-04-10 | 2021-09-14 | University Of Georgia Research Foundation, Inc. | Methods of using probenecid for treatment of coronavirus infections |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE158580T1 (de) * | 1993-05-06 | 1997-10-15 | Merrell Pharma Inc | Substituierte pyrrolidin-3-alkyl-piperidine verwendbar als tachykinin-antagonisten |
| US5635510A (en) * | 1993-05-06 | 1997-06-03 | Merrell Pharmaceuticals Inc. | Substituted pyrrolidin-3-yl-alkyl-piperidines |
| AU2223495A (en) * | 1994-04-15 | 1995-11-10 | Yamanouchi Pharmaceutical Co., Ltd. | Spiro compound and medicinal composition thereof |
| US5861417A (en) * | 1996-12-19 | 1999-01-19 | Hoechst Marion Roussel, Inc. | Heterocyclic substituted pyrrolidine amide derivatives |
| JP3558079B2 (ja) * | 2001-03-19 | 2004-08-25 | 小野薬品工業株式会社 | トリアザスピロ［５．５］ウンデカン誘導体およびそれらを有効成分とする薬剤 |
-
2003
- 2003-12-12 AU AU2003296992A patent/AU2003296992A1/en not_active Abandoned
- 2003-12-12 US US10/538,134 patent/US7271172B2/en not_active Expired - Fee Related
- 2003-12-12 ES ES03813415T patent/ES2309400T3/es not_active Expired - Lifetime
- 2003-12-12 WO PCT/US2003/039618 patent/WO2004055016A1/en not_active Ceased
- 2003-12-12 JP JP2004560830A patent/JP2006511552A/ja active Pending
- 2003-12-12 EP EP03813415A patent/EP1569933B1/en not_active Expired - Lifetime
- 2003-12-12 DE DE60322423T patent/DE60322423D1/de not_active Expired - Lifetime
- 2003-12-12 AT AT03813415T patent/ATE402176T1/de not_active IP Right Cessation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2006511552A5 (https=) | ||
| JP2006514950A5 (https=) | ||
| US8933086B2 (en) | Heteroaryl substituted pyrrolo[2,3-B]pyridines and pyrrolo[2,3-B]pyrimidines as Janus kinase inhibitors | |
| JP2006511555A5 (https=) | ||
| RU2399620C2 (ru) | Производные хинуклидина и их применение в качестве антагонистов мускариновых рецепторов м3 | |
| TWI395749B (zh) | 吡咯并〔１，２-ｂ〕嗒酮化合物 | |
| JP2007512299A5 (https=) | ||
| RU2019132212A (ru) | Селективные ингибиторы hdac6 | |
| JP2008513498A5 (https=) | ||
| JP2006512339A5 (https=) | ||
| RU2006144709A (ru) | Земещенные 2-хинолилоксазолы, пригодные в качестве ингибиторы фдэ4 | |
| JP2010502716A (ja) | インターロイキン１受容体関連キナーゼの調節物質 | |
| CN106573006A (zh) | 作为药物的rip1激酶抑制剂杂环酰胺 | |
| JP2008526761A5 (https=) | ||
| RU2013154117A (ru) | Производные 1-фенил-2-пиридинилалкильных спиртов в качестве ингибиторов фосфодиэстеразы | |
| HRP20140770T1 (hr) | SUPSTITUIRANI SPOJEVI N-(1H-INDAZOL-4-IL)IMIDAZO[1,2-a]PIRIDIN-3-KARBOKSAMIDA KAO INHIBITORI CFMS | |
| JP2020516671A5 (https=) | ||
| JP2005504080A5 (https=) | ||
| EP1953147A1 (en) | Heterocyclic compound and medicinal application thereof | |
| EA032028B1 (ru) | СТИМУЛЯТОРЫ рГЦ | |
| JP2004536869A5 (https=) | ||
| JP2015134783A (ja) | ５，６−ジヒドロ−１ｈ−ピリジン−２−オン化合物 | |
| JP2005508923A5 (https=) | ||
| JP2011524897A (ja) | β２−アドレナリン受容体活性の調節のための、４−ヒドロキシ−２−オキソ−２，３−ジヒドロ−１，３−ベンゾチアゾール−７−イル化合物を含む医薬組成物 | |
| CN1270591A (zh) | 新的化合物 |